REFERENCES
- Zarling J. M., Shoyab M., Marquardt H., Hanson M. B., Lioubin M. N., Todaro G. J. Oncostatin M: A Growth Regulator Produced by Differentiated Histiocytic Lymphoma Cells. Proc. Natl. Acad. Sci. USA 1986; 83: 9739–9743
- Brown T. J., Lioubin M. N., Marquardt H. Purification and Characterization of Cytostatic Lymphokines Produced by Activated Human T Lymphocytes. J. Immunol. 1987; 139: 2977–2983
- Loy J. K., Davidson T. J., Berry K. K., MacMaster J. F., Danle B., Durham S. K. Oncostatin M: Development of a Pleiotropic Cytokine. Toxicol. Pathol. 1999; 27: 151–155
- Rose T. M., Bruce A. G. Oncostatin M is a Member of a Cytokine Family that Includes Leukemia-Inhibitory Factor, Granulocyte Colony-Stimulating Factor, and Interleukin-6. Proc. Natl. Acad. Sci. USA 1991; 88: 8641–8645
- Malik N., Kallestad J. C., Gunderson N. L., Austin S. C., Neubauer M. G., Ochs V., Marquardt H., Zarling J. M., Shoyab M., Wei C.-M., Linsley P. S., Rose T. M. Molecular Cloning, Sequence Analysis, and Functional Expression of a Novel Growth Regulator. Oncostatin M. Mol. Cell. Biol. 1989; 9: 2847–2853
- Kallestad J. C., Shoyab M., Linsley P. S. Disulfide Bond Assignment and Identification of Regions Required for Functional Activity of Oncostatin M. J. Biol. Chem. 1991; 266: 8940–8945
- Von WorthingtonTypsinogen-Trypsin and Trypsin Inhibitors. Worthington Enzyme Manual, . Worthington Biochemical Corporation, Freehold, New Jersey 1993; 374–389
- Walsh K. G. Perlmann, L. LorandTrypsinogens and Trypsins of Various Species. Methods in Enzymology, XIX, . Academic Press, New York 1970; 41–63
- Manning M. C., Patel K., Borchardt R. T. Stability of Protein Pharmaceuticals. Pharm. Res. 1989; 6: 903–918
- Schöneich C., Hageman M. J., Borchardt R. T. P. KinamStability of Peptides and Proteins. Controlled Drug Delivery: Challenges and Strategies, . American Chemical Society, Washington, D.C. 1997; 205–228
- Becker G. W., Tackitt P. M., Bromer W. W., Lefeber D. S., Riggin R. M. Isolation and Characterization of a Sulfoxide and a Desamido Derivative of Biosynthetic Human Growth Hormone. Biotechnol. Appl. Biochem. 1988; 10: 326–337
- Johnson B. A., Shirokawa J. M., Hancock W. S., Spellman M. W., Basa L. J., Aswad D. W. Formation of Isoaspartate at two Distinct Sites During In Vitro Aging of Human Growth Hormone. J. Biol. Chem. 1989; 264: 14262–14271
- Steiner R., Frattali V. Purification and Properties of Soybean Protein Inhibitor of Proteolytic Enzymes. J. Agr. Food Chem. 1969; 17: 513–518
- Goswami J. Genetic Control of Death in Chinese Hamster Ovary Cell Cultures. Ph.D. Thesis, Massachusetts Institute of Technology. 1998
- Shadle P. J. J. A. BontempoDevelopment of Recovery Processes for Recombinant Proteins and Peptides. Development of Biopharmaceutical Parenteral Dosage Forms, . Marcel Dekker, New York 1997; 31–90
- Arathoon W. R., Builder S. E., Lubiniechi A. S., van Reis R. D. Process for Producing Biologically Active Plasminogen Activator in Recombinant CHO Cells Using Suspension Culture and Removing Detrimental Components from Media. US Patent 5, 053, 334, Oct 1, 1991
- Cunningham L. Molecular-kinetic Properties of Crystalline Diisopropyl Phosphoryl Trypsin. J. Biol. Chem. 1954; 211: 13–19